Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Molecular Therapy Nucleic Acids is Scopus-indexed (Q1, CiteScore 10.8), WoS SCIE, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by Cell Press.
Checked against the index lists dated .
ISSN 2162-2531Verify ISSN ↗
Publisher: Cell Press
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Drug Discovery | 23 / 161 | 86th | Q1 |
| Molecular Medicine | 27 / 179 | 85th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2012–present, best quartile Q1, CiteScore 10.8.
Molecular Therapy Nucleic Acids is Q1 in Drug Discovery (rank 23 of 161) and Q1 in Molecular Medicine (rank 27 of 179), by CiteScore 2025.
Molecular Therapy Nucleic Acids is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 10.8, which places it in quartile Q1 at the 86th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.068, quartile Q1, with an H-index of 113.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$3,900 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Molecular Therapy Nucleic Acids is published by Cell Press. Its ISSN is 2162-2531.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Molecular Therapy Nucleic Acids has an h-index of 131 and a 2-year mean of 5.17 citations per paper (OpenAlex). Its Scopus CiteScore is 10.8, quartile Q1. On 2-year citations it ranks #29 of 159 Scopus journals in Drug Discovery.
Molecular Therapy Nucleic Acids published 353 papers in 2025; its busiest recent year was 2020 with 385. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 72 research articles (2026), authors are most often from United States (35.1%), China (11.1%) and United Kingdom (7.6%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 174 retracted papers are recorded (50.8 per 1,000 papers). The Problematic Paper Screener flags 9 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.